The expression of genes measured at the end of treatment confirmed that improved tumor control is linked to a stronger inhibition of genes that report on the activity of MAPK signaling (e.g., FOSL1, DUSP6, and SPRY4). The gene discussed is FOSL1; the disease is neoplasm.